BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

219 related articles for article (PubMed ID: 32761426)

  • 1. Associations among the mutational landscape, immune microenvironment, and prognosis in Chinese patients with hepatocellular carcinoma.
    Hu ZQ; Xin HY; Luo CB; Li J; Zhou ZJ; Zou JX; Zhou SL
    Cancer Immunol Immunother; 2021 Feb; 70(2):377-389. PubMed ID: 32761426
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Impact of Immune Response on Outcomes in Hepatocellular Carcinoma: Association With Vascular Formation.
    Itoh S; Yoshizumi T; Yugawa K; Imai D; Yoshiya S; Takeishi K; Toshima T; Harada N; Ikegami T; Soejima Y; Kohashi K; Oda Y; Mori M
    Hepatology; 2020 Dec; 72(6):1987-1999. PubMed ID: 32112577
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prognostic analysis of tumor mutation burden and immune infiltration in hepatocellular carcinoma based on TCGA data.
    Liu S; Tang Q; Huang J; Zhan M; Zhao W; Yang X; Li Y; Qiu L; Zhang F; Lu L; He X
    Aging (Albany NY); 2021 Apr; 13(8):11257-11280. PubMed ID: 33820866
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comprehensive analysis of genomic and immunological profiles in Chinese and Western hepatocellular carcinoma populations.
    Li W; Wu H; Xu X; Zhang Y
    Aging (Albany NY); 2021 Apr; 13(8):11564-11594. PubMed ID: 33867349
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Whole-exome sequencing and immune profiling of early-stage lung adenocarcinoma with fully annotated clinical follow-up.
    Kadara H; Choi M; Zhang J; Parra ER; Rodriguez-Canales J; Gaffney SG; Zhao Z; Behrens C; Fujimoto J; Chow C; Yoo Y; Kalhor N; Moran C; Rimm D; Swisher S; Gibbons DL; Heymach J; Kaftan E; Townsend JP; Lynch TJ; Schlessinger J; Lee J; Lifton RP; Wistuba II; Herbst RS
    Ann Oncol; 2017 Jan; 28(1):75-82. PubMed ID: 27687306
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Preferential Expression of Programmed Death Ligand 1 Protein in Tumor-Associated Macrophages and Its Potential Role in Immunotherapy for Hepatocellular Carcinoma.
    Park DJ; Sung PS; Lee GW; Cho S; Kim SM; Kang BY; Hur W; Yang H; Lee SK; Lee SH; Jung ES; Seo CH; Ahn J; Choi HJ; You YK; Jang JW; Bae SH; Choi JY; Yoon SK
    Int J Mol Sci; 2021 Apr; 22(9):. PubMed ID: 33946835
    [TBL] [Abstract][Full Text] [Related]  

  • 7. TREM2
    Tan J; Fan W; Liu T; Zhu B; Liu Y; Wang S; Wu J; Liu J; Zou F; Wei J; Liu L; Zhang X; Zhuang J; Wang Y; Lin H; Huang X; Chen S; Kuang M; Li J
    J Hepatol; 2023 Jul; 79(1):126-140. PubMed ID: 36889359
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Reliability of a single-region sample to evaluate tumor immune microenvironment in hepatocellular carcinoma.
    Shen YC; Hsu CL; Jeng YM; Ho MC; Ho CM; Yeh CP; Yeh CY; Hsu MC; Hu RH; Cheng AL
    J Hepatol; 2020 Mar; 72(3):489-497. PubMed ID: 31634533
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Tumor-Associated Neutrophils Recruit Macrophages and T-Regulatory Cells to Promote Progression of Hepatocellular Carcinoma and Resistance to Sorafenib.
    Zhou SL; Zhou ZJ; Hu ZQ; Huang XW; Wang Z; Chen EB; Fan J; Cao Y; Dai Z; Zhou J
    Gastroenterology; 2016 Jun; 150(7):1646-1658.e17. PubMed ID: 26924089
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The spatial distribution of immune cell subpopulations in hepatocellular carcinoma.
    Wang PC; Hu ZQ; Zhou SL; Yu SY; Mao L; Su S; Li J; Ren N; Huang XW
    Cancer Sci; 2022 Feb; 113(2):423-431. PubMed ID: 34779545
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Relationship Between PD-L1 Expression and CD8+ T-cell Immune Responses in Hepatocellular Carcinoma.
    Huang CY; Wang Y; Luo GY; Han F; Li YQ; Zhou ZG; Xu GL
    J Immunother; 2017; 40(9):323-333. PubMed ID: 29028787
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Disruption of tumour-associated macrophage trafficking by the osteopontin-induced colony-stimulating factor-1 signalling sensitises hepatocellular carcinoma to anti-PD-L1 blockade.
    Zhu Y; Yang J; Xu D; Gao XM; Zhang Z; Hsu JL; Li CW; Lim SO; Sheng YY; Zhang Y; Li JH; Luo Q; Zheng Y; Zhao Y; Lu L; Jia HL; Hung MC; Dong QZ; Qin LX
    Gut; 2019 Sep; 68(9):1653-1666. PubMed ID: 30902885
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Identification of immunological subtypes of hepatocellular carcinoma with expression profiling of immune-modulating genes.
    Cao D; Chen MK; Zhang QF; Zhou YF; Zhang MY; Mai SJ; Zhang YJ; Chen MS; Li XX; Wang HY
    Aging (Albany NY); 2020 Jun; 12(12):12187-12205. PubMed ID: 32544882
    [TBL] [Abstract][Full Text] [Related]  

  • 14. EOGT Correlated With Immune Infiltration: A Candidate Prognostic Biomarker for Hepatocellular Carcinoma.
    Shu Y; He L; Gao M; Xiao F; Yang J; Wang S; Wei H; Zhang F; Wei H
    Front Immunol; 2021; 12():780509. PubMed ID: 35069551
    [TBL] [Abstract][Full Text] [Related]  

  • 15. High-mobility group protein box1 expression correlates with peritumoral macrophage infiltration and unfavorable prognosis in patients with hepatocellular carcinoma and cirrhosis.
    Zhang QB; Jia QA; Wang H; Hu CX; Sun D; Jiang RD; Zhang ZL
    BMC Cancer; 2016 Nov; 16(1):880. PubMed ID: 27836008
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Tumor suppressor gene mutations correlate with prognosis and immunotherapy benefit in hepatocellular carcinoma.
    Liu Z; Liu L; Guo C; Yu S; Meng L; Zhou X; Han X
    Int Immunopharmacol; 2021 Dec; 101(Pt B):108340. PubMed ID: 34789428
    [TBL] [Abstract][Full Text] [Related]  

  • 17. VISTA expression associated with CD8 confers a favorable immune microenvironment and better overall survival in hepatocellular carcinoma.
    Zhang M; Pang HJ; Zhao W; Li YF; Yan LX; Dong ZY; He XF
    BMC Cancer; 2018 May; 18(1):511. PubMed ID: 29720116
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Heterogeneous immunogenomic features and distinct escape mechanisms in multifocal hepatocellular carcinoma.
    Dong LQ; Peng LH; Ma LJ; Liu DB; Zhang S; Luo SZ; Rao JH; Zhu HW; Yang SX; Xi SJ; Chen M; Xie FF; Li FQ; Li WH; Ye C; Lin LY; Wang YJ; Wang XY; Gao DM; Zhou H; Yang HM; Wang J; Zhu SD; Wang XD; Cao Y; Zhou J; Fan J; Wu K; Gao Q
    J Hepatol; 2020 May; 72(5):896-908. PubMed ID: 31887370
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Genomic landscape and its correlations with tumor mutational burden, PD-L1 expression, and immune cells infiltration in Chinese lung squamous cell carcinoma.
    Jiang T; Shi J; Dong Z; Hou L; Zhao C; Li X; Mao B; Zhu W; Guo X; Zhang H; He J; Chen X; Su C; Ren S; Wu C; Zhou C
    J Hematol Oncol; 2019 Jul; 12(1):75. PubMed ID: 31299995
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Peritumoral Tertiary Lymphoid Structures Correlate With Protective Immunity and Improved Prognosis in Patients With Hepatocellular Carcinoma.
    Li H; Liu H; Fu H; Li J; Xu L; Wang G; Wu H
    Front Immunol; 2021; 12():648812. PubMed ID: 34122408
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.